The Management Board and Supervisory Board of MorphoSys AG (MOR) recommended that shareholders accept the offer by Novartis and tender their MorphoSys shares. Novartis offers MorphoSys shareholders 68.00 euros per share in cash, representing a total equity value of 2.7 billion euros.
MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital.
Jean-Paul Kress, CEO of MorphoSys, said: "After conducting a thorough assessment of the offer document, we unanimously conclude that the offer, including the offer price, is highly attractive and equitable."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.